论文部分内容阅读
目的研究替吉奥联合紫杉醇对进展期胃癌的疗效和安全性。方法选择2013年9月—2015年12月在濮阳市油田总医院进行诊治的进展期胃癌患者80例,按随机数字表法分为两组。观察组给予替吉奥、顺铂联合紫杉醇治疗,对照组给予替吉奥和紫杉醇治疗。两组患者均以21 d为1个周期,均接受2个周期的治疗。观察两组患者的近期疗效、远期疗效和不良反应发生情况。结果观察组的有效率为52.50%(21/40),明显高于对照组的40.00%(16/40),两组比较差异显著(P<0.05);两组的中位无进展生存时间、中位总生存时间和1年生存率相比无明显差异;两组患者主要的不良反应为骨髓抑制及消化道反应,且多为0~Ⅱ度。观察组的恶心呕吐反应与对照组相比明显较轻(P<0.05),其他不良反应两组相比无明显差异。结论替吉奥、顺铂联合紫杉醇对进展期胃癌具有较好的临床疗效,且安全性较高,值得临床推广应用。
Objective To study the efficacy and safety of tegaserod combined with paclitaxel in advanced gastric cancer. Methods Seventy patients with advanced gastric cancer diagnosed and treated in Puyang Oilfield General Hospital from September 2013 to December 2015 were divided into two groups according to random number table. The observation group was treated with tegaserod and cisplatin combined with paclitaxel, and the control group with tiotropium and paclitaxel. Two groups of patients were 21 d for a cycle, are receiving two cycles of treatment. Observation of two groups of patients with short-term efficacy, long-term efficacy and adverse reactions. Results The effective rate of the observation group was 52.50% (21/40), which was significantly higher than that of the control group (40.00%, 16/40) (P <0.05). The median progression-free survival time, The median overall survival time and 1-year survival rate compared with no significant difference; two groups of patients with major adverse reactions of bone marrow suppression and gastrointestinal reactions, and mostly 0 to 2 degrees. Nausea and vomiting in the observation group was significantly lower than that in the control group (P <0.05). There was no significant difference in other adverse reactions between the two groups. Conclusion TEGO, cisplatin combined with paclitaxel for advanced gastric cancer has a good clinical efficacy, and high safety, it is worth promoting the clinical application.